BIOMARIN PHARMACEUTICAL INC Accounts Payable and Other Accrued Liabilities, Current
BIOMARIN PHARMACEUTICAL INC (BMRN) had Accounts Payable and Other Accrued Liabilities, Current of $406.98 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Payables and Accruals
us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Accounts Payable and Other Accrued Liabilities, Current $406.98M.
- 2026-03-31: Accounts Payable and Other Accrued Liabilities, Current $395.47M.
- 2025-12-31: Accounts Payable and Other Accrued Liabilities, Current $312.77M.
- 2025-09-30: Accounts Payable and Other Accrued Liabilities, Current $389.67M.
| Period end | Accounts Payable and Other Accrued Liabilities, Current | Accounts Payable and Other Accrued Liabilities, Current as first filed |
|---|---|---|
| 2026-06-30 | $406.98M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $395.47M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $312.77M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $389.67M 10-Q · filed 2025-10-28 | |
| 2025-06-30 | $310.80M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $293.75M 10-Q · filed 2025-05-02 | |
| 2024-12-31 | $235.40M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $312.32M 10-Q · filed 2024-10-31 | |
| 2024-06-30 | $257.41M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $292.24M 10-Q · filed 2024-04-26 | |
| 2023-12-31 | $315.51M 10-K · filed 2025-02-24 | |
| 2023-09-30 | $301.37M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $277.94M 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $264.78M 10-Q · filed 2023-04-28 | |
| 2022-12-31 | $231.24M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $207.16M 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $199.25M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $187.81M 10-Q · filed 2022-04-29 | |
| 2021-12-31 | $199.68M 10-K · filed 2023-02-27 | $193.00M 10-K · filed 2022-02-25 |
| 2021-09-30 | $203.32M 10-Q · filed 2021-10-29 | |
| 2021-06-30 | $176.07M 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $165.00M 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $191.43M 10-K · filed 2022-02-25 | |
| 2020-09-30 | $218.02M 10-Q · filed 2020-11-06 | |
| 2020-06-30 | $205.87M 10-Q · filed 2020-08-05 | |
| 2020-03-31 | $235.16M 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $240.98M 10-K · filed 2021-02-26 | |
| 2019-09-30 | $226.77M 10-Q/A · filed 2019-11-04 | |
| 2019-06-30 | $223.95M 10-Q · filed 2019-08-02 | |
| 2019-03-31 | $224.38M 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $207.62M 10-K · filed 2020-02-27 | |
| 2018-09-30 | $177.40M 10-Q · filed 2018-10-26 | |
| 2018-06-30 | $166.42M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $172.19M 10-Q · filed 2018-04-27 | |
| 2017-12-31 | $166.62M 10-K · filed 2019-02-28 | |
| 2017-09-30 | $157.02M 10-Q · filed 2017-10-31 | |
| 2017-06-30 | $158.23M 10-Q · filed 2017-08-02 | |
| 2017-03-31 | $135.60M 10-Q · filed 2017-05-04 | |
| 2016-12-31 | $191.35M 10-K · filed 2018-02-26 | |
| 2016-09-30 | $148.77M 10-Q · filed 2016-11-03 | |
| 2016-06-30 | $153.65M 10-Q · filed 2016-08-08 | |
| 2016-03-31 | $152.86M 10-Q · filed 2016-05-02 | |
| 2015-12-31 | $179.29M 10-K · filed 2017-02-27 | |
| 2015-09-30 | $162.93M 10-Q · filed 2015-11-02 | |
| 2014-12-31 | $139.51M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |